Mycoplasma Anti-Microbial Resistance Patterns In Yaounde Cameroon
Authors: Gideon Kehfen Wiysenyuy1*, Shei Claude Nfor, Chifam Berthe, Atanga Desmond Funwie2. Paper Title: Mycoplasma Anti-Microbial Resistance Patterns In Yaounde Cameroon .IQ Research Journal of IQ res. j. (2023)2(1): pp 01-07. Vol. 002, Issue 01, 01-2023, pp. 001-007
Antimicrobial resistance (AMR) is one of the greatest concerns in medical care worldwide and threatens to reverse most of the gains modern medicine brought with the discovery of antimicrobials. Majority of patients received in Etoug-ebe Baptist Hospital Yaounde (EBHY) are treated with antimicrobials. Successful treatment of genital mycoplasma infection remains a priority in a city like Yaounde where prevalence amongst women stands at 65% and has been implicated in. pelvic inflammatory disease, puerperal infection, septic abortions, low birth weight, nongonococcal urethritis and prostatitis as well as spontaneous abortion and infertility in women. The aim of the study was to obtain antimicrobial resistance patterns for mycoplasma amongst patients in EBHY. The objectives
were to obtain the growth yield rate from microbial culture and sensitivity (MCS) samples in EBHY and to obtain MCS rates in patients served in EBHY, and identify resistance/sensitivity patterns of mycoplasma in EBHY.
The study was a cross-sectional uni-centre retrospective review of MCS results recorded in EBHY in 2016. The recorded data for that year was extracted, tallied, collated and analyzed. The study revealed that mycoplasma organisms showed a mean of 50% resistance (range 24-80%) to some drugs reviewed. There was considerable resistance to tetracycline, tobramycin and to a lower extent
azithromycin and ciprofloxacin. Also, of 103 samples cultured for mycoplasma, 30 (29.12%) did not yield any growth. We can conclude that there is a high resistance of mycoplasma to common antibiotics used in EBHY and client treatment should follow resistant pattern guidelines outlined in this research for a successful antimicrobial treatment outcom